Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal stem cells (Cleveland Clinic)
- Development stage
- Unknown
- Lead developer
- Cleveland Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous mesenchymal stem cell (MSC) therapy is an investigational biologic developed by the Cleveland Clinic for the treatment of relapsing forms of multiple sclerosis (MS). The therapy involves the extraction of a patient's own bone marrow-derived MSCs, which are then culture-expanded ex vivo before being re-administered via intravenous infusion. The mechanism of action is hypothesized to involve immunomodulation and the paracrine release of soluble trophic factors that promote tissue protection and repair within the central nervous system. A Phase 1 pilot study (NCT00813969) led by Dr. Jeffrey Cohen demonstrated that the treatment is feasible, safe, and well-tolerated in patients with relapsing-remitting or secondary progressive MS, supporting further clinical investigation.
- Other names
- autologous bone marrow-derived mesenchymal stem cellsautologous MSCsMSC transplantation
Beyond the preview
Go deeper on autologous mesenchymal stem cells (Cleveland Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal stem cells (Cleveland Clinic).